Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia using the Etest method

被引:27
作者
Jones, RN
Salazar, JC
Pfaller, MA
Doern, GV
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA
[2] Fdn Valle Lili, Cali, Colombia
关键词
D O I
10.1016/S0732-8893(97)00157-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The need for comprehensive and quantitative accurate antimicrobial resistance surveillance systems has become acute as a guide to problem recognition and to focus local interventions. A multilaboratory (10 medical centers) Colombia surveillance project was initiated in early 1997 to monitor the potency and spectrum of six (cefepime, cefotaxime, ceftazidime, cefoperazone/sulbactam, aztreonam, and imipenem) broad-spectrum antimicrobial agents tested against 100 organisms per participant center (802 strains). Ten groups of organisms were tested by a reference-quality method (Etest; AB BIODISK, Solna, Sweden) with results validated by concurrent quality control and additional challenge strain analysis. Results from nine qualifying medical centers were tabulated, and 95.7 to 96.8% of quality assurance tests were within expected ranges. Only cefepime (90.1-100.0% susceptible) and imipenem (96.3-100.0%) were active against all Enterobacteriaceae at >90% of susceptible isolates using the breakpoint concentrations recommended by the National Committee for Clinical Laboratory Standards. Among ceftazidime- (or cefotaxime- or aztreonam-) resistant Enterobacter spp. and Citrobacter freundii, cefepime remained active, but not cefoperazone with sulbactam. Escherichia coli and Klebsiella spp. strains having resistance phenotypes consistent with extended spectrum beta-lactamase production were discovered in approximately 5 to 10% of isolates. All tested drugs except ceftazidime (31.8-57.7% susceptible) were active against >94% of oxacillin-susceptible staphylococci. Similar rates of resistance (9.1-14.8%) were observed in Pseudomonas aeruginosa for five of six drugs (not cefotaxime; 15.9% of strains were susceptible). Acinetobacter spp. isolates were most susceptible to imipenem (95.8%), cefepime (86.1%), and cefoperazone/sulbactam (83.3%). Overall for the 1997 order of antimicrobial spectrums for these tested compounds was: imipenem (96.6%) > cefepime (93.6%) > cefoperazone/sulbactam (90.5%) > cefotaxime (74.9%) > aztreonam (74.3% for Gram-negative bacilli only) > ceftazidime (73.2%). These data should be used to guide empiric regimens in Colombia, and additionally will provide a resistance statistical baseline to which future studies in this nation can be compared. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 31 条
[1]   CEFEPIME - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE [J].
BARRADELL, LB ;
BRYSON, HM .
DRUGS, 1994, 47 (03) :471-505
[2]   CRITERIA FOR DISK SUSCEPTIBILITY TESTS AND QUALITY-CONTROL GUIDELINES FOR THE CEFOPERAZONE-SULBACTAM COMBINATION [J].
BARRY, AL ;
JONES, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (01) :13-17
[3]  
BERNE TV, 1993, SURG GYNECOL OBSTET, V177, P18
[4]   EVALUATION OF THE E-TEST, A NOVEL METHOD OF QUANTIFYING ANTIMICROBIAL ACTIVITY [J].
BROWN, DFJ ;
BROWN, L .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (02) :185-190
[5]   Distribution of capsular types and antimicrobial susceptibility of invasive isolates of Streptococcus pneumoniae in Colombian children [J].
Castaneda, E ;
Leal, AL ;
Castillo, O ;
DeLaHoz, F ;
Vela, MC ;
Arango, M ;
Trujillo, H ;
Levy, A ;
Gama, ME ;
Calle, M ;
Valencia, ML ;
Parra, W ;
Agudelo, N ;
Mejia, GI ;
Jaramillo, S ;
Montoya, F ;
Porras, H ;
Sanchez, A ;
Saa, D ;
DiFAbio, JL ;
Homma, A ;
Rios, AM ;
Ovalle, MV ;
Serrato, J ;
Navarrete, MR ;
Garcia, M ;
Aristizabal, G ;
Tovar, A ;
Paredes, C ;
Arenas, A ;
Zapata, C ;
Robledo, J ;
Correa, N ;
Suarez, C ;
Garcia, V ;
Gallardo, LM ;
Moreno, A ;
Villamarin, N ;
Bohorquez, AL ;
Lopez, P ;
Guerrero, J .
MICROBIAL DRUG RESISTANCE, 1997, 3 (02) :147-152
[6]   ANTIMICROBIAL ACTIVITY OF FK-037, A NEW BROAD-SPECTRUM CEPHALOSPORIN - INTERNATIONAL IN-VITRO COMPARISON WITH CEFEPIME AND CEFTAZIDIME [J].
FREI, R ;
JONES, RN ;
PIGNATARI, AC ;
YAMANE, N ;
MARCO, F ;
HOBAN, DJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1994, 18 (03) :167-173
[7]   Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins [J].
FungTomc, JC ;
Gradelski, E ;
Huczko, E ;
Dougherty, TJ ;
Kessler, RE ;
Bonner, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1289-1293
[8]   A NONCOMPARATIVE STUDY OF THE EFFICACY AND TOLERANCE OF CEFEPIME IN COMBINATION WITH AMIKACIN IN THE TREATMENT OF SEVERE INFECTIONS IN PATIENTS IN INTENSIVE-CARE [J].
GOUIN, F ;
PAPAZIAN, L ;
MARTIN, C ;
ALBANESE, J ;
DURBEC, O ;
DOMART, Y ;
VEYSSIER, P ;
LEROY, J ;
GRES, JJ ;
ROLLIN, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :205-214
[9]  
HANCOCK REW, 1992, J ANTIMICROB CHEMOTH, V29, P1
[10]   INTERNATIONAL COMPARATIVE-STUDY OF CEFEPIME AND CEFTAZIDIME IN THE TREATMENT OF SERIOUS BACTERIAL-INFECTIONS [J].
HOEPELMAN, AIM ;
KIEFT, H ;
AOUN, M ;
KOSMIDIS, J ;
STRAND, T ;
VERHOEF, J ;
GILLESPIE, SH ;
RIDDELL, J ;
VARGHESE, G ;
MEUNIER, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :175-186